News
DGAP-Adhoc: Biotest AG: Biotest exceeds Revenue guidance 2021
DGAP-Adhoc: Biotest AG: Biotest übertrifft Umsatz Prognose 2021
Forbes Names AMN Healthcare to America’s Best Employers List
AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the nation, today announced it was named among America’s Best Employers for 2022
DGAP-HV: Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 30.03.2022 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2021 and reaffirmed guidance for 2022. For the quarter, revenue was $905.1
Agilent Announces Cash Dividend of 21 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on April 27, 2022, to all shareholders of record as of the close of
AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human
European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment
HAEMATO adds a new generation test device to its portfolio
HAEMATO nimmt Corona Testgerät der neuen Generation in ihr Portfolio auf
Vifor Pharma gibt Markteinführung von Tavneos® in Deutschland bekannt
Vifor Pharma Deutschland GmbH hat heute die Markteinführung von Tavneos® bekannt gegeben, der ersten in Europa zugelassenen oralen Therapie für die Behandlung der beiden Haupttypen von
Dexcom Announces Upcoming Virtual Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences:
-
Brice Bobzien, Vice President, Finance
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use
Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports positive biomarker data from the ongoing
DGAP-News: Carl Zeiss Meditec erzielt weiteres Wachstum im ersten Quartal 2021/22
DGAP-News: Carl Zeiss Meditec achieves further growth in first quarter of 2021/22
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets. Clovis’
Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2021.
Fourth Quarter 2021 Financial Highlights:
-
Revenue grew 23%
Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
DGAP-HV: MeVis Medical Solutions AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.03.2022 in Bremen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Transgene Appoints Steven Bloom as Chief Business Officer
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced today that it has appointed
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities